David Scadden - 28 Jun 2022 Form 4 Insider Report for Magenta Therapeutics, Inc. (MGTA)

Role
Director
Signature
/s/ Cindy Driscoll, Attorney-in-Fact for David Scadden
Issuer symbol
MGTA
Transactions as of
28 Jun 2022
Transactions value $
$0
Form type
4
Filing time
30 Jun 2022, 18:33:55 UTC
Previous filing
23 Jun 2022
Next filing
05 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGTA Stock Option (Right to Buy) Award $0 +20K $0.00 20K 28 Jun 2022 Common Stock 20K $1.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders.

Remarks:

Exhibit 24.1: Power of Attorney